We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Brain Cancer

Expert Opinion / Cases · September 27, 2021

Managing Progressive Diffuse Midline Glioma H3 K27M-Mutant

Written by
L. Nicolas Gonzalez Castro MD, PhD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Dorothy-Myra Sackey

    Sep 28, 2021

    proceed on maintainance temozolomide for the mutation

  • Michela Pisani

    Oct 01, 2021

    Cyberknife rt

  • Isacco Desideri

    Oct 01, 2021

    Maintainance temozolomide plus focal irradation with any high precision radiotherapy technique

  • Tolga Tuncer

    Dec 06, 2021

    Clinical Trial assessment for ONC201 or compassionate use vs SRS

  • Amir Azadi

    Dec 20, 2021

    Clinical Trial assessment for ONC201 or Regorafenib vs. LITT 

  • Jul 04, 2022

    Pending Moderator approval.

Further Reading